The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis

BACKGROUND: In hormone-receptor positive/HER2-negative metastatic breast cancer (mBC) no randomized comparisons are available between CDK4/6 inhibitors. We undertook this systematic review and meta-analysis to assess the reliability of the likelihood of being helped or harmed (LHH). METHODS: PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrantoni, Luca, Orlandi, Armando, Palazzo, Antonella, Garufi, Giovanna, Fabi, Alessandra, Daniele, Gennaro, Giannarelli, Diana, Tortora, Giampaolo, Bria, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874016/
https://www.ncbi.nlm.nih.gov/pubmed/36713467
http://dx.doi.org/10.1016/j.eclinm.2023.101824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874016/
https://www.ncbi.nlm.nih.gov/pubmed/36713467
http://dx.doi.org/10.1016/j.eclinm.2023.101824

Ejemplares similares